Utilisation de la prévention des TMS pour un changement culturel dans l’exploitation minière: partenariat entre le gouvernement du Queensland et l’Anglo Coal Industry.

Queensland Mining places a strong emphasis on safety performance, but managing health risks, including musculoskeletal disorders (MSDs), continues to have a lower priority. The use of individual worker screening and lower level approaches such as manual handling training are part of the coal mining ‘culture’. Initiatives such as the New South Wales and Queensland Mining joint project to develop good practice guidelines for mining have helped to spread a more consistent message on participatory ergonomics and MSD prevention. A practical, evidence-based approach, including the introduction of participatory ergonomics and safe design principles, was offered for Anglo American Coal operations in Queensland.

The project consisted of an analysis of the skills of current health workers, the design of a facilitated participatory ergonomics training program, site visits to identify good practices and champions, and a graduated mentoring program for the personal health. Initial results show that a number of sites benefit from site working groups focused on positive performance results. and a graduated mentoring program for health workers. Initial results show that a number of sites benefit from site working groups focused on positive performance results. and a graduated mentoring program for health workers. Initial results show that a number of sites benefit from site working groups focused on positive performance results.

Prevention of MSDs through an ergonomic risk assessment (tools) in all phases of the vehicle development process.

In industrialized countries, musculoskeletal disorders (MSDs) play an important role and are often responsible for almost a third of all sick leaves. Changing demographic profiles, i.e. the aging of the workforce, could even worsen this situation in the future. For a highly productive and sustainable use of human resources in production systems, ergonomics offers high potential. In recent years, the authors have developed several ergonomic risk assessment tools, particularly for use in automotive industries. These methods can be used during the planning phases in Tech Centers as well as during the production phase at the shop floor.

The tools could also be used for standardized communication between the Tech Center and factories to improve the effects of “lessons learned” for the design and layout of workstations and processes and the optimization of vehicle components. . This article describes the appropriate risk assessment tools as well as the integration of these tools into the vehicle development process. It introduces a global management approach for the integration of ergonomics in the management of production systems. optimization of vehicle components.

This article describes the appropriate risk assessment tools as well as the integration of these tools into the vehicle development process. It introduces a global management approach for the integration of ergonomics in the management of production systems. optimization of vehicle components. This article describes the appropriate risk assessment tools as well as the integration of these tools into the vehicle development process. It introduces a global management approach for the integration of ergonomics in the management of production systems.

Innovation in the profession of occupational physician requires the development of a working group to improve the effectiveness of MSD prevention.

Given the aging population of occupational physicians and the deterioration in the health of employees, reforms aimed at the multidisciplinary nature of occupational health are being drawn up. These are of great concern to physicians with regard to the future of occupational health, especially with regard to the evolution of medical practices. The objective of this study is to explore the actual practices of occupational physicians in the context of the prevention of MSDs in France. By analyzing the activity of occupational physicians, we could better understand the coordination between OSH actors with the ultimate goal of improving prevention.

Utilisation de la prévention des TMS pour un changement culturel dans l'exploitation minière: partenariat entre le gouvernement du Queensland et l'Anglo Coal Industry.

Based on an analysis of peer activity, this method made it possible to go beyond the pre-constructed discourse. According to the theories of activity, it is through others that the history and controversies of a profession can be understood and skills developed. The results produced by these collective discussions on the analysis of activities helped to establish a collective point of view on the important aspects of their profession to be defended and the variations of professional gender in relation to the current reforms, in particular.

Multiple sclerosis documentation system (MSDS): moving from documentation to the management of patients with MS.

The long duration of multiple sclerosis disease and the increasing treatment options require an individualized therapeutic approach that must be carefully documented over years of observation. To move from MS documentation to innovative MS management, new IT and Internet tools could be implemented, as we have been able to demonstrate with the new patient management IT system “Multiple Sclerosis Management System 3D ”(MSDS 3D). MSDS 3D allows the documentation and management of visiting schedules and compulsory examinations via study modules defined by the integration of input data from various sources (patients, treating physicians and MS nurses).

It provides forms for documenting patient visits as well as clinical and diagnostic results. Information can be collected through interactive touch screens. Specific modules allow the management of highly effective treatments such as natalizumab or fingolimod. The MSDS can be used to transfer documented data to databases such as e.g. the register of the German company MS or REGIMS. The MSDS has already been successfully implemented in clinical practice and is currently being evaluated in a multi-center environment. High quality management and documentation are essential to improve clinical practice and research.

Information can be collected through interactive touch screens. Specific modules allow the management of highly effective treatments such as natalizumab or fingolimod. The MSDS can be used to transfer documented data to databases such as e.g. the register of the German company MS or REGIMS. The MSDS has already been successfully implemented in clinical practice and is currently being evaluated in a multi-center environment. High quality management and documentation are essential to improve clinical practice and research. Information can be collected through interactive touch screens.

Specific modules allow the management of highly effective treatments such as natalizumab or fingolimod. The MSDS can be used to transfer documented data to databases such as e.g. the register of the German company MS or REGIMS. The MSDS has already been successfully implemented in clinical practice and is currently being evaluated in a multi-center environment. High quality management and documentation are essential to improve clinical practice and research. The MSDS can be used to transfer documented data to databases such as e.g. the register of the German company MS or REGIMS. The MSDS has already been successfully implemented in clinical practice and is currently being evaluated in a multi-center environment. High quality management and documentation are essential to improve clinical practice and research.

Chlorpyrifos antibody

70-1070 500 ul
EUR 349
Description: Chicken polyclonal Chlorpyrifos antibody

Chlorpyrifos antibody

70-1071 50 ul
EUR 327
Description: Rabbit polyclonal Chlorpyrifos antibody

Chlorpyrifos ELISA Kit

DEIANJ22 96T
EUR 866
Description: The Chlorpyrifos ELISA is an immunoassay for the detection of chlorpyrifos in contaminated samples.

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Rabbit anti Bovine

E61I02501 0.1mg
EUR 343

Anti-Rabbit antibody

STJ11100323 100 µl
EUR 277

SensiTek Anti-Rabbit

ABE008 8 ml
EUR 71

SensiTek Anti-Rabbit

ABE015 15 ml
EUR 80

SensiTek Anti-Rabbit

ABE125 125 ml
EUR 176

SensiTek Anti-Rabbit

ABE500 500 ml
EUR 420

SensiTek Anti-Rabbit

ABE999 1000 ml
EUR 711

UltraTek Anti-Rabbit

ABK008 8 ml
EUR 80

UltraTek Anti-Rabbit

ABK015 15 ml
EUR 98

UltraTek Anti-Rabbit

ABK125 125 ml
EUR 228

UltraTek Anti-Rabbit

ABK500 500 ml
EUR 554

UltraTek Anti-Rabbit

ABK999 1000 ml
EUR 934

Polyclonal Rabbit anti-sEH

SEH-1 50 uL
EUR 280

Rabbit Anti Human IgG

E61I00101 100ug
EUR 343

Rabbit anti mouse IgG

E61I00901 100ug
EUR 343

Rabbit anti Sheep IgG

E61I01001 100ul
EUR 343

Rabbit anti Goat IgG

E61I01002 1mg
EUR 343

Rabbit anti RBC IgG

E61I01102 1mg
EUR 343

goat Anti Rabbit IgG

E61I01301 1mg
EUR 274

Rabbit Anti FITC Antibody

E61I01402 100ug
EUR 343

Rabbit anti Chicken IgY

E61I0201 100ug
EUR 343

Rabbit anti Pig IgG

E61I02301 0.1mg
EUR 343

Rabbit anti Horse IgG

E61I02401 0.1mg
EUR 343

Polyclonal Rabbit anti-GAPDH

DRD96417 50 uL
EUR 280

Rabbit anti-Vaccinia antiserum

01-0003 250uL
EUR 451
Description:
  • Related to: Other Viruses
  • Applications: ELISA, WB

Rabbit anti-Junin antiserum

01-0006 250uL
EUR 451
Description:
  • Related to: Other Viruses
  • Applications: ELISA, WB

Rabbit anti-LukA pAb

0316-001 100ug
EUR 354
Description:
  • Related to: Staphylococcus
  • Applications: ELISA, WB

Rabbit anti-LukB pAb

0317-001 100ug
EUR 354
Description:
  • Related to: Staphylococcus
  • Applications: ELISA, WB

Rabbit anti-Junin pAb

04-0006 500ug
EUR 257
Description:
  • Related to: Other Viruses
  • Applications: ELISA, WB

Rabbit anti-Hla pAb

04-0010 500ug
EUR 303
Description:
  • Related to: Staphylococcus
  • Applications: ELISA, WB

Anti-Rabbit IgG antibody

STJ16101370 1 mg
EUR 214

Anti-Rabbit IgG antibody

STJ16101371 1.2 mg
EUR 257

Anti-Rabbit IgG antibody

STJ16101372 1.2 mg
EUR 306

Anti-Rabbit IgG antibody

STJ16101375 1 mg
EUR 538

Polyclonal Rabbit Anti-HSA

C020101-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-HSA

C020101-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-BSA

C020102-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-BSA

C020102-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-HRP

C020103-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-HRP

C020103-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-OVA

C020105-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-OVA

C020105-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-FITC

C020115-10mg 10mg
EUR 3058

Polyclonal Rabbit Anti-FITC

C020115-1mg 1mg
EUR 523

Polyclonal Rabbit Anti-Biotin

C020116-10mg 10mg
EUR 3058

Polyclonal Rabbit Anti-Biotin

C020116-1mg 1mg
EUR 523

Polyclonal Rabbit Anti-SPA

C020117-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-SPA

C020117-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-SPG

C020118-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-SPG

C020118-1mg 1mg
EUR 201

Polyclonal Rabbit Anti-SA

C020120-10mg 10mg
EUR 861

Polyclonal Rabbit Anti-SA

C020120-1mg 1mg
EUR 201

Anti-Rabbit IgG antibody

STJ99246 200 µl
EUR 197
Description: Mouse monoclonal to Rabbit IgG.

Rabbit Anti-Serotonin antiserum

SER21-S 100 ul
EUR 457

Rabbit Anti-mPEG antiserum

PEG11-S 100 ul
EUR 408

Rabbit Anti-Phosphotyrosine antiserum

PTYR11-S 100 ul
EUR 457

Rabbit anti- mouse IgA

FNab09894 100µg
EUR 548.75
Description: Antibody raised against Rabbit mouse IgA

Rabbit Anti-Monkey IgG

FNSA-0099 500 uL
EUR 306.6
Description: Rabbit Anti-Monkey IgG secondary antibody

Rabbit Anti-Glutathione IgG

GSH11-A 100 ul
EUR 482

Rabbit anti- mouse IgA

LSMab09894 100 ug
EUR 386

Rabbit anti-SAM b

PA00201-100 100µg
EUR 738
Description: Rabbit polyclonal antibody to S-Adenosylmethionine

Rabbit anti-SAM a

PA00201-50 50µg
EUR 445
Description: Rabbit polyclonal antibody to S-Adenosylmethionine

Rabbit anti-MAT s

PA00401-50 50µg
EUR 221
Description: Rabbit polyclonal antiserum against methionine adenosyltransferase

Rabbit anti-MAT g

PA00402-50 50µg
EUR 221
Description: Rabbit polyclonal antiserum against methionine adenosyltransferase with glycerol

Rabbit anti Mouse IgM

20-B80010000-U4 10 ml
EUR 192
Description: Rabbit anti Mouse IgM antibody

Rabbit anti Chicken IgY

20-B9093R000-R0 5 ml
EUR 138
Description: Rabbit anti Chicken IgY antibody

Rabbit anti Human IgE

20-IR77 1 ml
EUR 192
Description: Rabbit anti Human IgE antibody

Rabbit anti Goat IgG

20-S5801R000-VO 10 ml
EUR 133
Description: Rabbit anti Goat IgG antibody

Mouse anti Rabbit IgG

40-1005 1 mg
EUR 349
Description: Mouse anti Rabbit IgG secondary antibody

Mouse anti Rabbit IgG

40-1006 1 mg
EUR 349
Description: Mouse anti Rabbit IgG secondary antibody

Rabbit anti Mouse IgM

40-B9201R000-R0 5 ml
EUR 133
Description: Rabbit anti Mouse IgM secondary antibody

Goat anti Rabbit IgG

40-GR30 100 ml
EUR 241
Description: Goat anti Rabbit IgG secondary antibody

Goat anti Rabbit IgG

40-GR30S 100 ml
EUR 133
Description: Goat anti Rabbit IgG secondary antibody

Rabbit anti Sheep IgG

40-RS50 100 ml
EUR 133
Description: Rabbit anti Sheep IgG secondary antibody

Sheep anti Rabbit IgG

40-SR35 250 ml
EUR 133
Description: Sheep anti Rabbit IgG secondary antibody

Rabbit anti Bovine IgG

40C-CB0115 2 mg
EUR 281
Description: Rabbit anti Bovine IgG secondary antibody

Rabbit anti Bovine IgG

40C-CB0129 5 mg
EUR 347
Description: Rabbit anti Bovine IgG secondary antibody

Rabbit anti Cat IgG

40C-CB0222 2 mg
EUR 248
Description: Rabbit anti Cat IgG secondary antibody

Rabbit anti Chicken IgG

40C-CB0322 5 mg
EUR 346
Description: Rabbit anti Chicken IgG secondary antibody

Rabbit anti Dog IgG

40C-CB0408 2 mg
EUR 273
Description: Rabbit anti Dog IgG secondary antibody

Rabbit anti Dog IgG

40C-CB0415 5 mg
EUR 347
Description: Rabbit anti Dog IgG secondary antibody

Rabbit anti Goat IgG

40C-CB0536 1.5 mg
EUR 269
Description: Rabbit anti Goat IgG secondary antibody

Rabbit anti Human IgG

40C-CB0943 1 mg
EUR 249
Description: Rabbit anti Human IgG secondary antibody

Rabbit anti Human IgG

40C-CB0950 5 mg
EUR 381
Description: Rabbit anti Human IgG secondary antibody

Rabbit anti Human IgG

40C-CB0971 2 mg
EUR 322
Description: Rabbit anti Human IgG secondary antibody

Goat anti Rabbit IgG

40C-CB1157 5 mg
EUR 311
Description: Goat anti Rabbit IgG secondary antibody

The MSDS can be used to transfer documented data to databases such as e.g. the register of the German company MS or REGIMS. The MSDS has already been successfully implemented in clinical practice and is currently being evaluated in a multi-center environment. High quality management and documentation are essential to improve clinical practice and research.